LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3. - Dataset (ID:20239)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Mitoxantrone | 0.04 | uM | LJP6 | 3 | C24 | 72 | hr | 1401 | 1579 | 4223 | 0.3739 | 0.0629 |
| SK-BR-3 | MK2206 | 0.04 | uM | LJP6 | 1 | F06 | 72 | hr | 1401 | 3216 | 4223 | 0.7615 | 0.6431 |
| SK-BR-3 | MK2206 | 0.04 | uM | LJP6 | 2 | F06 | 72 | hr | 1401 | 2906 | 4223 | 0.6881 | 0.5332 |
| SK-BR-3 | MK2206 | 0.04 | uM | LJP6 | 3 | F06 | 72 | hr | 1401 | 3111 | 4223 | 0.7367 | 0.6059 |
| SK-BR-3 | Neratinib | 0.04 | uM | LJP5 | 1 | A18 | 72 | hr | 1401 | 1374 | 4223 | 0.3254 | -0.0098 |
| SK-BR-3 | Neratinib | 0.04 | uM | LJP5 | 2 | A18 | 72 | hr | 1401 | 1725 | 4223 | 0.4085 | 0.1146 |
| SK-BR-3 | Neratinib | 0.04 | uM | LJP5 | 3 | A18 | 72 | hr | 1401 | 1515 | 4223 | 0.3587 | 0.0402 |
| SK-BR-3 | Nilotinib | 0.04 | uM | LJP5 | 1 | N18 | 72 | hr | 1401 | 4496 | 4223 | 1.0646 | 1.0967 |
| SK-BR-3 | Nilotinib | 0.04 | uM | LJP5 | 2 | N18 | 72 | hr | 1401 | 4747 | 4223 | 1.1241 | 1.1857 |
| SK-BR-3 | Nilotinib | 0.04 | uM | LJP5 | 3 | N18 | 72 | hr | 1401 | 4934 | 4223 | 1.1683 | 1.2520 |
| SK-BR-3 | Nintedanib | 0.04 | uM | LJP6 | 1 | H06 | 72 | hr | 1401 | 4499 | 4223 | 1.0653 | 1.0978 |
| SK-BR-3 | Nintedanib | 0.04 | uM | LJP6 | 2 | H06 | 72 | hr | 1401 | 4163 | 4223 | 0.9858 | 0.9787 |
| SK-BR-3 | Nintedanib | 0.04 | uM | LJP6 | 3 | H06 | 72 | hr | 1401 | 4634 | 4223 | 1.0973 | 1.1456 |
| SK-BR-3 | NU7441 | 0.04 | uM | LJP5 | 1 | C12 | 72 | hr | 1401 | 4500 | 4223 | 1.0656 | 1.0981 |
| SK-BR-3 | NU7441 | 0.04 | uM | LJP5 | 2 | C12 | 72 | hr | 1401 | 4341 | 4223 | 1.0279 | 1.0418 |
| SK-BR-3 | NU7441 | 0.04 | uM | LJP5 | 3 | C12 | 72 | hr | 1401 | 4359 | 4223 | 1.0322 | 1.0482 |
| SK-BR-3 | Dactolisib | 0.04 | uM | LJP5 | 1 | M18 | 72 | hr | 1401 | 1484 | 4223 | 0.3514 | 0.0292 |
| SK-BR-3 | Dactolisib | 0.04 | uM | LJP5 | 2 | M18 | 72 | hr | 1401 | 1673 | 4223 | 0.3962 | 0.0962 |
| SK-BR-3 | Dactolisib | 0.04 | uM | LJP5 | 3 | M18 | 72 | hr | 1401 | 1517 | 4223 | 0.3592 | 0.0409 |
| SK-BR-3 | NVP-TAE684 | 0.04 | uM | LJP6 | 1 | K18 | 72 | hr | 1401 | 4044 | 4223 | 0.9576 | 0.9365 |
| SK-BR-3 | NVP-TAE684 | 0.04 | uM | LJP6 | 2 | K18 | 72 | hr | 1401 | 4203 | 4223 | 0.9952 | 0.9929 |
| SK-BR-3 | NVP-TAE684 | 0.04 | uM | LJP6 | 3 | K18 | 72 | hr | 1401 | 4540 | 4223 | 1.0750 | 1.1123 |
| SK-BR-3 | Palbociclib | 0.04 | uM | LJP6 | 1 | E18 | 72 | hr | 1401 | 3369 | 4223 | 0.7978 | 0.6973 |
| SK-BR-3 | Palbociclib | 0.04 | uM | LJP6 | 2 | E18 | 72 | hr | 1401 | 3024 | 4223 | 0.7161 | 0.5750 |
| SK-BR-3 | Palbociclib | 0.04 | uM | LJP6 | 3 | E18 | 72 | hr | 1401 | 3221 | 4223 | 0.7627 | 0.6449 |